I. Skin Cancers

a. Epidemiologic/Correlative

UCI 09-17 Biology of Human Melanocytes and Keratinocytes (Meyskens)

UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-01 Suspended (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

b. Prevention

UCI 14-92 Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

c. Screening/Diagnostic

UCI 11-30 Skin imaging with Technologies in Development (Kelly)

UCI 13-13 Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

UCI 15-08 Spectral comparison betweenSpatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon**
b. Screening/Diagnostic

- **UCI 16-37** **Pending**
  Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

- **UCI 16-45**
  A Phase 1/ Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma (Pinter-Brown)

- **UCI 16-46**
  A Phase I Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

a. Therapeutic

- **UCI 16-96**
  A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

- **SWOG S1609** (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

IV. Miscellaneous & Phase 1 Clinical Trials

- **UCI 17-50** **Pending**
  A Multicenter, Phase 1/ Ib, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

- **UCI 17-58** **Pending**
  Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu **Opening soon**

Version 2/18